CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Les brevets les plus récents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team


Novel anti-infectious glycomimetic compounds



Statut des brevets

PCT priority patent application PCT/IB2010/055741 filed on December the 10, 2010 and entitled « Glycomimetic compounds as anti-infectious against pathogens lectins »


Sébastien VIDAL
Benoit GUERY
Karine FAURE

Statut commercial

Exclusive or non-exclusive licenses



Pathogens such as Pseudomonas aeruginosa produce a large number of protein receptors called lectins that are able to specifically recognize carbohydrates located on human tissues.

These receptors are known to play a primary role in the infection by such pathogens as they participate in the adhesion to host tissues through the recognition of carbohydrate epitopes leading to the formation of biofilm which increases the resistance to host immunity.

Carbohydrates and derivatives with high affinity toward lectins that can interfere with the adhesion process of pathogens are a promising source of anti-infectious compounds for pathogens whom infection is based on lectins. Such compounds consequently appear as an alternative to the use of antibiotics which tends to be less efficient with bacteria such as Pseudomonas aeruginosa.


In the present work, the inventors have developped novel glycomimetic compounds presenting anti-adhesive properties due to a high affinity towards bacterial lectins competiting therefore with human tissue oligosaccharides.

The compounds of the present work comprise a calixarene core linked to 2, 3 or 4 carbohydrates with several spacer arms presenting different binding properties.


  • In vitro and in vivo efficiency assays with Pseudomonas aeruginosa;
  • Future development : toxicity assays.


Glycomimetic compounds protected in the invention have many benefits:

  • They can be used locally;
  • They do not display any toxicity;
  • There is a weak risk of pathogen resistance (as they do not affect bacteria metabolism);
  • They can be potentially used in conjunction with other treatments such as antibiotics.


As already stated, the glycomimetic compounds of the present invention can be used as anti-infectious therapeutic agents. For example, they can be used through inhalation in the treatment of infections involving Pseudomonas aeruginosa, the pyocyanic bacillus involved in lung infection in cystic fibrosis patients. Moreover,
knowing that such pathogens can also be present in skin infections, another application could be the local application on band aid of said compounds.
Finally, to prevent nosocomial infections involving Pseudomonas aeruginosa, another application could be based on the treatment of hospital equipments respiratory apparatus, surgery tools) as well as regular surfaces or even hands.

For further information, please contact us (Ref 03949-01)

Besoin de plus d'informations ?

Nous contacter


  • This field is for validation purposes and should be left unchanged.

Les brevets les plus récents